Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio?
ImmuneOnco Biopharmaceuticals (Shanghai)FRA:R9Z +11.52%7 PB Ratio is 1.66 as of Aug. 12, 2026, which is 59% below its 10-year median of 4.09. GuruFocus rates FRA:R9Z with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 1,222 Biotechnology companies, ImmuneOnco Biopharmaceuticals (Shanghai) ranks better than 66.04% on this metric.
FRA:R9Z's PB Ratio is ranked better than 66.04% of 1222
companies
in the Biotechnology industry
Industry Median: 2.92
vs FRA:R9Z: 1.81
During the past 12 months, ImmuneOnco Biopharmaceuticals (Shanghai)'s average Book Value Per Share Growth Rate was 13.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.60% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of ImmuneOnco Biopharmaceuticals (Shanghai) was -4.60% per year. The lowest was -4.60% per year. And the median was -4.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio Related Terms
ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio Chart
ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
2.53
2.82
ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio vs Biotechnology Industry
ImmuneOnco Biopharmaceuticals (Shanghai) PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a PB Ratio of 1.66 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. This is 59% below median its historical median of 4.09. Over the past decade, ImmuneOnco Biopharmaceuticals (Shanghai)'s PB Ratio has ranged from 1.45 to 13.28. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #415 out of 1222 companies in the Biotechnology industry, placing it in the top 34%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s PB Ratio too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current PB Ratio of 1.66 is 59% below median its 10-year median of 4.09. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 13.28. The Biotechnology industry median PB Ratio is 2.92. ImmuneOnco Biopharmaceuticals (Shanghai)'s value of 1.66 is 43.2% below this industry median. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #415 out of 1222 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #415 out of 1222 companies for PB Ratio. This puts ImmuneOnco Biopharmaceuticals (Shanghai) in the upper half of its industry. The industry median PB Ratio is 2.92. ImmuneOnco Biopharmaceuticals (Shanghai)'s value of 1.66 is 43.2% below this benchmark. Historically, ImmuneOnco Biopharmaceuticals (Shanghai)'s own PB Ratio has ranged from 1.45 to 13.28 over the past decade. While the company's 10-year median is 4.09 vs. the industry median of 2.92, ImmuneOnco Biopharmaceuticals (Shanghai) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,222 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuneOnco Biopharmaceuticals (Shanghai)'s current PB Ratio of 1.66 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuneOnco Biopharmaceuticals (Shanghai)'s current PB Ratio is 1.66, which is 59% below median its own 10-year median of 4.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current PB Ratio of 1.66. The current PB Ratio is 1.66, which is 59% below median its 10-year median of 4.09 and 43.2% below the Biotechnology industry median of 2.92. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current PB Ratio is 1.66 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
7GF Score
Get the complete analysis for FRA:R9Z
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R9Z has been successfully added to your 
